文献速递鼻科

美泊利单抗治疗重度未控制慢性鼻窦炎伴鼻息肉的一年真实世界疗效

One year mepolizumab outcomes in severe, uncontrolled CRSwNP: a real-life study.
PubMed 文献 · Rhinology · 2025-01-01

本研究在真实临床环境中纳入50例接受美泊利单抗100 mg每4周一次治疗的重度未控制慢性鼻窦炎伴鼻息肉(CRSwNP)患者,评估其作为鼻用糖皮质激素(INCS)附加治疗第一年的疗效。治疗12个月后,鼻息肉评分中位数从5降至2,SNOT-22评分均值从58.4±21降至26.1±17.5,嗅觉仅轻度改善(VAS中位数从10降至6)。7例患者仍控制不佳,需全身性激素治疗,其中5例还接受内镜鼻窦手术。

要点

  • 美泊利单抗治疗12个月后鼻息肉评分中位数从5降至2。
  • SNOT-22评分均值从58.4±21降至26.1±17.5。
  • 嗅觉VAS中位数仅从10降至6,改善有限。

核心结论

  • 结果支持美泊利单抗作为重度未控制CRSwNP现行标准治疗中的有效选择,尤其在缩小鼻息肉体积和改善生活质量方面,但对嗅觉恢复影响较小。

研究设计与样本

  • 真实世界研究,纳入50例重度未控制CRSwNP患者(28例男性;平均年龄56.4岁,范围35-77岁),接受美泊利单抗100 mg每4周一次作为INCS附加治疗,评估第一年疗效。

主要发现

  • 治疗12个月后鼻息肉评分中位数从5降至2。
  • SNOT-22评分均值从58.4±21降至26.1±17.5。
  • 嗅觉VAS中位数从基线10降至12个月时6,仅轻度改善。
  • 7例患者仍控制不佳需全身性激素治疗,其中5例还接受内镜鼻窦手术。

临床怎么用

  • 作者认为美泊利单抗可作为重度未控制CRSwNP现行标准治疗中的有效选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study aimed to evaluate the effectiveness of mepolizumab in the treatment of severe, uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) as add-on therapy to intranasal corticosteroids (INCS) in a real-life setting over the first year of treatment. METHODOLOGY: We included 50 patients (28 males; mean age: 56.4 years, range 35-77) who received mepolizumab 100 mg every 4 weeks. The primary objective of this study was to evaluate the reduction in nasal polyp size and improvement in patients' quality of life, measured through symptom-based questionnaires. The secondary objective was to evaluate improvements in smell dysfunction, severity of comorbidities, blood eosinophilia, and the need for surgery or systemic steroids. RESULTS: After 12 months of treatment, the median nasal polyp score (NPS) decreased from 5 to 2 and the mean sino-nasal outcome test-22 (SNOT-22) score decreased from 58.4±21 to 26.1±17.5. Olfaction only slightly improved with a median VAS score decreasing from 10 at baseline to 6 at 12 months. Seven patients remained uncontrolled and required systemic steroids and in 5 cases also endoscopic sinus surgery. CONCLUSIONS: The results support the use of mepolizumab as an effective option in the current standard of care for patients affected by severe, uncontrolled CRSwNP especially in decreasing nasal polyps’ size and improving quality of life, although a minor impact was observed on recovery of smell.

来源:Rhinology,查看原文。版权归原作者所有。

引用

  1. De Corso E, Corbi M, De Maio G, et al. One year mepolizumab outcomes in severe, uncontrolled CRSwNP: a real-life study. Rhinology. 2025. PMID: 40631514. doi:10.4193/Rhin25.121

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。